Effect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive Patients

Hypertension Clinical Trial

Official title:

Effect of Different Antihypertensive Treatment on Serum Uric Acid in Newly Diagnosed Hypertensive Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04554069
• Other study ID #: Uric acid in Hypertension
• Status: Not yet recruiting
• Start date: June 1, 2021
• Est. completion date: February 2022

Study information

• Verified date: January 2021
• Source: Assiut University
• Contact: Mentallah Abdelrahman, MBBCH
• Phone: +201092772639
• Email: menahallah.osama[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Assessment of the influence of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension patients.

Description:

Hypertension is the most common condition seen in primary care and leads to myocardial infarction, stroke, renal failure, and death if not detected early and treated appropriately.

Thiazide-type diuretics, angiotensin-converting enzyme (ACE) inhibitors and some of angiotensin-II receptor blockers (ARB) were reported to reduce renal excretion of urate and increased serum uric acid levels, Beta-blockers also elevate serum uric acid levels.

Hyperuricemia is a risk factor for cardiovascular diseases. Hyperuricemia was found to correlate with hypertension excluding the influence of other factors such as age and renal function. Furthermore, many studies found that hyperuricemia was independently associated with cardiovascular events in patients treated with antihypertensive drugs.

It is important to control serum uric acid levels in hypertensive patients treated with antihypertensive drugs in order to reduce the risk of gout and cardiovascular events. There is a gap in knowledge in studies showing the effect of antihypertensive drugs on serum uric acid in newly diagnosed hypertensive patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 280
• Est. completion date: February 2022
• Est. primary completion date: January 2022
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• All newly diagnosed hypertensive patients aged 30 years old and above will be invited to participate in this study

Exclusion Criteria:

1. Patients below 30 years old.

2. Patients with kidney disease.

3. Patients who are taking medications known to increase SUA as (Thiazide and Loop diuretics, Salicylates, Cyclosporin use) or decrease the level of uric acid in the urine as (Allopurinol, Febuoxstate).

Related Conditions & MeSH terms

• Hypertension

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (2)

Shankar A, Klein R, Klein BE, Nieto FJ. The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. J Hum Hypertens. 2006 Dec;20(12):937-45. Epub 2006 Oct 5. — View Citation

Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000 Dec;36(6):1072-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The effect of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension.	we will measure the change of the level of serum uric acid after 6 months from the treatment of antihypertensive durgs	6 months from baseline
Secondary	obesity	it will be measured by BMI (kg/m2)	6 months from baseline